{"id":238522,"date":"2026-05-06T13:04:14","date_gmt":"2026-05-06T13:04:14","guid":{"rendered":"https:\/\/www.europesays.com\/se\/238522\/"},"modified":"2026-05-06T13:04:14","modified_gmt":"2026-05-06T13:04:14","slug":"novo-nordisk-okade-rorelseresultatet-kraftigt","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/238522\/","title":{"rendered":"Novo Nordisk \u00f6kade r\u00f6relseresultatet kraftigt"},"content":{"rendered":"

Danska l\u00e4kemedelsbolaget Novo Nordisk redovisar \u00f6kad oms\u00e4ttning och h\u00f6gre r\u00f6relseresultat under f\u00f6rsta kvartalet j\u00e4mf\u00f6rt med samma period \u00e5ret innan.<\/p>\n

Oms\u00e4ttningen steg 24 procent till 96 823 miljoner danska kronor (78 087).<\/p>\n

R\u00f6relseresultatet blev 59 618 miljoner danska kronor (38 791).<\/p>\n

Det justerade r\u00f6relseresultatet sj\u00f6nk 15 procent till 32 858 miljoner danska kronor.<\/p>\n

Resultatet efter skatt blev 48 557 miljoner danska kronor (29 034).<\/p>\n

Novo Nordisks fetmal\u00e4kemedel Wegovy i tablettform lanserades i USA den 5 januari. F\u00f6r veckan som slutade den 17 april \u00f6versteg antalet recept 200 000 och totalt har fler \u00e4n 2 miljoner recept skrivits sedan lanseringen, vilket enligt bolaget g\u00f6r det till den starkaste GLP-1-lanseringen volymm\u00e4ssigt i USA hittills.<\/p>\n

F\u00f6rs\u00e4ljningen f\u00f6r Wegovy-tabletten uppgick till 2,3 miljarder danska kronor under f\u00f6rsta kvartalet, p\u00e5verkat av lageruppbyggnad hos grossister och teleh\u00e4lsopartners inf\u00f6r lanseringen. De f\u00f6rsta lanseringarna utanf\u00f6r USA v\u00e4ntas under andra halv\u00e5ret 2026, f\u00f6rutsatt regulatoriska godk\u00e4nnanden.<\/p>\n

Novo Nordisk h\u00f6jer prognosen f\u00f6r 2026 efter h\u00f6gre f\u00f6rv\u00e4ntad f\u00f6rs\u00e4ljning av GLP-1-l\u00e4kemedel. Den justerade f\u00f6rs\u00e4ljningstillv\u00e4xten f\u00f6r 2026, exklusive \u00e5terf\u00f6ring av 340B-reserveringar, v\u00e4ntas nu bli minus 4 till minus 12 procent i fasta v\u00e4xelkurser. Den justerade r\u00f6relseresultattillv\u00e4xten, exklusive samma effekt, v\u00e4ntas ocks\u00e5 bli minus 4 till minus 12 procent i fasta v\u00e4xelkurser.<\/p>\n

Den f\u00f6rra prognosen sp\u00e5dde en tillv\u00e4xt om -5 till -13 procent f\u00f6r den justerade r\u00f6relsevinsten.<\/p>\n

\u201dWegovy:s starka resultat, i kombination med fortsatt tillv\u00e4xt inom den internationella verksamheten, har f\u00e5tt oss att h\u00f6ja v\u00e5ra prognoser f\u00f6r 2026 g\u00e4llande b\u00e5de justerad oms\u00e4ttning och justerat r\u00f6relseresultat\u201d, kommenterar Mike Doustdar, vd och koncernchef f\u00f6r Novo Nordisk.
<\/p>\n\n

Novo Nordisk, Mdkk<\/p>\n

Q1-2026<\/p>\n

Q1-2025<\/p>\n

F\u00f6r\u00e4ndring<\/p>\n<\/tr>\n\n\n

Nettooms\u00e4ttning<\/p>\n<\/td>\n\n

96 823<\/p>\n<\/td>\n\n

78 087<\/p>\n<\/td>\n\n

24,0%<\/p>\n<\/td>\n<\/tr>\n\n\n

R\u00f6relseresultat<\/p>\n<\/td>\n\n

59 618<\/p>\n<\/td>\n\n

38 791<\/p>\n<\/td>\n\n

53,7%<\/p>\n<\/td>\n<\/tr>\n\n\n

R\u00f6relsemarginal<\/p>\n<\/td>\n\n

61,6%<\/p>\n<\/td>\n\n

49,7%<\/p>\n<\/td>\n<\/tr>\n\n\n

Nettoresultat<\/p>\n<\/td>\n\n

48 557<\/p>\n<\/td>\n\n

29 034<\/p>\n<\/td>\n\n

67,2%<\/p>\n<\/td>\n<\/tr>\n","protected":false},"excerpt":{"rendered":"Danska l\u00e4kemedelsbolaget Novo Nordisk redovisar \u00f6kad oms\u00e4ttning och h\u00f6gre r\u00f6relseresultat under f\u00f6rsta kvartalet j\u00e4mf\u00f6rt med samma period \u00e5ret…\n","protected":false},"author":2,"featured_media":238523,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[22,23,26,27,17,21,24,25,28,29,15,6456,6457,16,18,34,31,33,32,30,19,20],"class_list":{"0":"post-238522","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-rubriker","8":"tag-breaking-news","9":"tag-breakingnews","10":"tag-featured-news","11":"tag-featurednews","12":"tag-headlines","13":"tag-huvudnyheter","14":"tag-latest-news","15":"tag-latestnews","16":"tag-main-news","17":"tag-mainnews","18":"tag-news","19":"tag-novo-nordisk-adr","20":"tag-novo-nordisk-b","21":"tag-nyheter","22":"tag-rubriker","23":"tag-se","24":"tag-svenska","25":"tag-sverige","26":"tag-sweden","27":"tag-swedish","28":"tag-top-stories","29":"tag-topstories"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/116527776738229037","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/238522","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=238522"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/238522\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/238523"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=238522"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=238522"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=238522"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}